These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27846946)

  • 41. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
    De Souza A; Strober BE; Merola JF; Oliver S; Franks AG
    J Drugs Dermatol; 2012 Oct; 11(10):1224-6. PubMed ID: 23134988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
    Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis.
    Garcet S; Nograles K; Correa da Rosa J; Schafer PH; Krueger JG
    J Allergy Clin Immunol; 2018 Sep; 142(3):1010-1013.e6. PubMed ID: 29936103
    [No Abstract]   [Full Text] [Related]  

  • 44. Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs.
    Harrison C
    Nat Rev Drug Discov; 2013 May; 12(5):335. PubMed ID: 23629496
    [No Abstract]   [Full Text] [Related]  

  • 45. Psoriasis vulgaris associated with systemic lupus erythematosus successfully treated with apremilast.
    Ichiyama S; Hoashi T; Kanda N; Hashimoto H; Matsushita M; Nozawa K; Ueno T; Saeki H
    J Dermatol; 2019 Jun; 46(6):e219-e221. PubMed ID: 30536461
    [No Abstract]   [Full Text] [Related]  

  • 46. Multiple lentigines in psoriasis patients treated with etanercept.
    Almazán-Fernández FM; Fernández-Crehuet P
    Eur J Dermatol; 2015; 25(4):354-6. PubMed ID: 26065690
    [No Abstract]   [Full Text] [Related]  

  • 47. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.
    Pacifico A; d'Arino A; Pigatto PDM; Malagoli P; Young Dermatologists Italian Network ; Damiani G
    Clin Exp Dermatol; 2021 Oct; 46(7):1344-1346. PubMed ID: 33969530
    [No Abstract]   [Full Text] [Related]  

  • 48. Phosphodiesterase 4-targeted treatments for autoimmune diseases.
    Kumar N; Goldminz AM; Kim N; Gottlieb AB
    BMC Med; 2013 Apr; 11():96. PubMed ID: 23557064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
    Pathan E; Abraham S; Van Rossen E; Withrington R; Keat A; Charles PJ; Paterson E; Chowdhury M; McClinton C; Taylor PC
    Ann Rheum Dis; 2013 Sep; 72(9):1475-80. PubMed ID: 22984171
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
    Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment with apremilast was beneficial for chronic graft-versus-host disease skin lesion in a patient with psoriasis.
    Ichiyama S; Komatsu T; Hoashi T; Kanda N; Nagai K; Yamada Y; Ansai SI; Saeki H
    J Dermatol; 2019 Jun; 46(6):e218-e219. PubMed ID: 30632183
    [No Abstract]   [Full Text] [Related]  

  • 53. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
    Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
    N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
    Papp KA; Kaufmann R; Thaçi D; Hu C; Sutherland D; Rohane P
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e376-83. PubMed ID: 23030767
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.
    Chiricozzi A; Caposiena D; Garofalo V; Cannizzaro MV; Chimenti S; Saraceno R
    Expert Rev Clin Immunol; 2016; 12(3):237-49. PubMed ID: 26692125
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).
    Edwards CJ; Blanco FJ; Crowley J; Birbara CA; Jaworski J; Aelion J; Stevens RM; Vessey A; Zhan X; Bird P
    Ann Rheum Dis; 2016 Jun; 75(6):1065-73. PubMed ID: 26792812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.
    Ighani A; Georgakopoulos JR; Walsh S; Shear NH; Yeung J
    J Am Acad Dermatol; 2018 Mar; 78(3):623-626. PubMed ID: 28989112
    [No Abstract]   [Full Text] [Related]  

  • 58. Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    J Am Acad Dermatol; 2018 Apr; 78(4):801-803. PubMed ID: 29017843
    [No Abstract]   [Full Text] [Related]  

  • 59. Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting.
    Lee EB; Amin M; Egeberg A; Wu JJ
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):e393-e394. PubMed ID: 29730885
    [No Abstract]   [Full Text] [Related]  

  • 60. ▼ Apremilast for psoriasis and psoriatic arthritis.
    Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.